Solanezumab for Alzheimer's disease

Abstract

Solanezumab can neutralize soluble Aβ peptides, which may represent the more neurotoxic of the Aβ species. Phase II findings support the compound's safety, which has been a concern for some Aβ immunotherapies. Cerebrospinal and plasma biomarker changes with solanezumab treatment are encouraging. Results of the ongoing Phase III trials will be instrumental in determining the drug's clinical significance.

Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology

“…31,32 Other clinic al trials with passive immunotherapy confirmed the occasional appearance of microhemorrhage and the occurrence of vasogenic edema in some individuals, particularly those with apolipoprotein E ε4 genotypes. 31,33 Nonetheless, several ongoing clinical trials with different amyloid β fragments and with humanized amyloid β antibodies are likely to indicate not only the importance of amyloid β in Alzheimer disease pathogenesis, but also whether anti amyloid β therapy can modify the disease pathology.…”

Modern Approaches to Diagnostics and Therapy of Alzheimer Disease

“…Этот метод основыва-ется на введении моно-или поликлональных антител, связывающих и выводящих из головного мозга амило-идный белок. Представлены данные клинических иссле-дований двух препаратов -соланезумаба [27] и ганте-нерумаба [21,22]. В настоящее время наиболее изучен-ным и зарекомендовавшим себя препаратом является гантенерумаб.…”

Emerging amyloid disease-modifying drugs for Alzheimer’s disease

“…[ Two humanized mAbs have been first developed: bapineuzumab (Pfizer), directed against the N-terminal region of Aβ peptide [9] and solanezumab (Eli Lilly), directed against Aβ central region. [10] Prior to the completion of the Phase II study, a phase III trial with bapineuzumab was initiated. The results of these trials did not show overall efficacy but a small subset of patients, namely the ApoE E4 non-carriers, responded well.…”